Breaking News

Catalent Completes RheinCell Therapeutics Acquisition

Plans to facilitate accelerated access to high-quality iPSC banks with integrated solutions from plasmid DNA manufacturing to clinical supply.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent has completed the acquisition of RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). RheinCell’s iPSC tools, services and expertise offers the building blocks to industrialize iPSC-based cell therapies and complements Catalent’s existing iPSC process development and manufacturing capabilities.   Catalent plans to facilitate accelerated access to these high-quality iPSC banks by leveraging its broad and expanding network....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters